Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Revenue (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Revenue for 16 consecutive years, with $185.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 23.72% year-over-year to $185.2 million, compared with a TTM value of $634.2 million through Dec 2025, up 20.05%, and an annual FY2025 reading of $634.2 million, up 20.05% over the prior year.
  • Revenue was $185.2 million for Q4 2025 at Amicus Therapeutics, up from $169.1 million in the prior quarter.
  • Across five years, Revenue topped out at $185.2 million in Q4 2025 and bottomed at $66.4 million in Q1 2021.
  • Average Revenue over 5 years is $109.8 million, with a median of $99.0 million recorded in 2023.
  • The sharpest move saw Revenue grew 2.7% in 2022, then skyrocketed 36.73% in 2024.
  • Year by year, Revenue stood at $82.2 million in 2021, then grew by 7.23% to $88.1 million in 2022, then skyrocketed by 30.63% to $115.1 million in 2023, then surged by 30.09% to $149.7 million in 2024, then increased by 23.72% to $185.2 million in 2025.
  • Business Quant data shows Revenue for FOLD at $185.2 million in Q4 2025, $169.1 million in Q3 2025, and $154.7 million in Q2 2025.